Bretton Fund Completes Exit from Revvity (RVTY) in 2025

Bretton Fund, a private investment firm with a focus on healthcare and life sciences, fully exited its holdings in Revvity Inc. (RVTY) by March 2025, according to public filings. The transaction, which involved the liquidation of approximately 1.2 million shares, represents a complete divestment from the biotechnology firm. The exit occurred amid a broader reassessment of portfolio allocations, with no indication of operational or financial distress at Revvity. Revvity, headquartered in Lexington, Massachusetts, specializes in providing analytical instruments and services to pharmaceutical and academic research institutions. The company operates in a highly specialized segment of the biotech sector, serving niche markets with limited direct correlation to broader equity trends. The divestment by Bretton Fund—whose prior stake was valued at roughly $140 million based on RVTY’s average share price in 2024—did not trigger significant price volatility in the stock. RVTY’s share price remained stable following the disclosure, closing at $116.80 on March 1, 2025, reflecting minimal market reaction. Industry analysts note that institutional exits of this nature are common in concentrated portfolios and do not necessarily signal broader sectoral weakness. The transaction underscores the private fund’s strategy of maintaining flexibility in a volatile healthcare environment. The exit may influence other long-term investors to reassess their exposure to mid-cap biotech firms with limited revenue diversification. However, Revvity continues to report positive R&D progress, including the launch of two new assay platforms in late 2024, which remain key drivers for investor interest.